Business
BIOF: No sales in Q2, but capital raised and promising tests set stage for scale-up and new leadership
BIOF: No sales in Q2, but capital raised and promising tests set stage for scale-up and new leadership
About this update from Biofrigas Sweden Ab
Q2 2025 saw no net sales and continued losses, but promising facility tests and a US patent grant position the company for a key scale-up phase. Capital was raised through rights issues and loans, and a CEO transition is set for September.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
View stock analysis, news, and events for Biofrigas Sweden Ab